

# Peter R Sinnaeve

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9439374/publications.pdf>

Version: 2024-02-01

42  
papers

1,324  
citations

687220

13  
h-index

360920

35  
g-index

43  
all docs

43  
docs citations

43  
times ranked

2362  
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. <i>Lancet, The</i> , 2018, 391, 41-50.	6.3	307
2	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	1.2	296
3	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. <i>European Heart Journal</i> , 2016, 37, 1538.1-1549.	1.0	147
4	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020, 41, 4245-4255.	1.0	117
5	Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2588-2597.	1.2	53
6	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020, 41, 2248-2258.	1.0	51
7	Etiology and Long-Term Outcome of Patients Undergoing Pericardiocentesis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	43
8	Contemporary Mortality Differences Between Primary Percutaneous Coronary Intervention and Thrombolysis in ST-Segment Elevation Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2011, 171, 544-9.	4.3	37
9	Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute Cardiovascular Care (ACVC) association and the ESC council of Cardio-Oncology Part 1: acute coronary syndromes and acute pericardial diseases. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 947-959.	0.4	37
10	Impact of COVID-19-related public containment measures on the ST elevation myocardial infarction epidemic in Belgium: a nationwide, serial, cross-sectional study. <i>Acta Cardiologica</i> , 2021, 76, 863-869.	0.3	33
11	Low i>MTâ€CO1 </i> in Monocytes and Microvesicles Is Associated With Outcome in Patients With Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	28
12	Assessment of Physical Activity by Wearable Technology During Rehabilitation After Cardiac Surgery: Explorative Prospective Monocentric Observational Cohort Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e9865.	1.8	28
13	Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. <i>Blood Pressure</i> , 2017, 26, 321-331.	0.7	20
14	Managing in-hospital quality improvement: An importance-performance analysis to set priorities for ST-elevation myocardial infarction care. <i>European Journal of Cardiovascular Nursing</i> , 2018, 17, 535-542.	0.4	13
15	The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients. <i>American Heart Journal</i> , 2020, 226, 140-146.	1.2	13
16	Dual Antiplatelet Therapy De-escalation Strategies. <i>American Journal of Cardiology</i> , 2021, 144, S23-S31.	0.7	11
17	Better hospital context increases success of care pathway implementation on achieving greater teamwork: a multicenter study on STEMI care. <i>International Journal for Quality in Health Care</i> , 2019, 31, 442-448.	0.9	9
18	Heart team 2.0: A decision tree for minimally invasive and hybrid myocardial revascularization. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 382-391.	2.3	9

#	ARTICLE	IF	CITATIONS
19	Lack of evidence and standardization in care pathway documents for patients with ST-elevated myocardial infarction. <i>European Journal of Cardiovascular Nursing</i> , 2016, 15, e45-e51.	0.4	8
20	Prevention of Cardiogenic Shock After Acute Myocardial Infarction. <i>Circulation</i> , 2019, 139, 137-139.	1.6	7
21	Absorb Bioresorbable Vascular Scaffold in Complex Coronary Bifurcation Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	6
22	Care Pathway Effect on In-Hospital Care for ST-Elevation Myocardial Infarction. <i>Cardiology</i> , 2018, 140, 163-174.	0.6	5
23	RNA-sequencing reveals that STRN, ZNF484 and WNK1 add to the value of mitochondrial MT-COI and COX10 as markers of unstable coronary artery disease. <i>PLoS ONE</i> , 2019, 14, e0225621.	1.1	5
24	A plethora of manifestations following a <i>Mycoplasma pneumoniae</i> infection: a case report. <i>Acta Clinica Belgica</i> , 2020, 75, 229-234.	0.5	5
25	Primary Percutaneous Coronary Intervention Not Always the Best Reperfusion Strategy?. <i>Circulation</i> , 2014, 129, 1623-1625.	1.6	4
26	Mode of admission and its effect on adherence to reperfusion therapy guidelines in Belgian STEMI patients. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 461-467.	0.4	4
27	Transporting STEMI patients for primary PCI: a long and winding road paved with good intentions?. <i>European Heart Journal</i> , 2016, 37, 1041-1043.	1.0	4
28	Key interventions and quality indicators for quality improvement of STEMI care: a RAND Delphi survey. <i>Acta Cardiologica</i> , 2018, 73, 518-527.	0.3	4
29	Primary PCI and the indistinct 120 min time limit. <i>European Heart Journal</i> , 2020, 41, 867-869.	1.0	4
30	One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper. <i>Acta Cardiologica</i> , 2017, 72, 19-27.	0.3	3
31	Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial. <i>Value in Health</i> , 2019, 22, 1355-1361.	0.1	3
32	In-Vivo Vascular Healing Following Bifurcation Interventions with the Absorb Bioresorbable Vascular Scaffold. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 70-77.	0.3	3
33	Vulnerability to cardiac arrest in patients with ST elevation myocardial infarction: Is it time or patient dependent? Results from a nationwide observational study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, S153-S160.	0.4	2
34	Tremor mimicking ventricular tachycardia. <i>Cmaj</i> , 2015, 187, E326-E326.	0.9	1
35	Major adverse cardiovascular events while awaiting staged non-culprit percutaneous coronary intervention after ST-segment elevation myocardial infarction. <i>Acta Cardiologica</i> , 2019, 74, 60-64.	0.3	1
36	Adherence to quality indicators for ST-elevation myocardial infarction and its relation to mortality: a hospital network analysis from the Belgian STEMI database. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 601-607.	1.8	1

#	ARTICLE	IF	CITATIONS
37	Peripheral Blood RNAs and Left Ventricular Dysfunction after Myocardial Infarction: Towards Translation into Clinical Practice. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 213-221.	1.1	1
38	Life-threatening paraneoplastic cardiovascular events in ALK-positive anaplastic large cell lymphoma. <i>Annals of Hematology</i> , 2021, 100, 2851-2853.	0.8	1
39	No TROFI for Routine Post-Dilatation AfterÂBVS Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1878-1880.	1.1	0
40	Quality assessment in Belgian ST elevation myocardial infarction patients: results from the Belgian STEMI database. <i>Acta Cardiologica</i> , 2018, 73, 529-533.	0.3	0
41	Twoâ€year outcomes after percutaneous coronary intervention with drugâ€eluting stents or bareâ€metal stents in elderly patients with coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E607-E613.	0.7	0
42	Abstract 18226: Fibrinolysis Before Percutaneous Coronary Intervention Reduces the Rate of Cardiogenic Shock in Patients Presenting Within 3 Hours After Symptom Onset. <i>Circulation</i> , 2015, 132, .	1.6	0